Zobrazeno 1 - 10
of 27
pro vyhledávání: '"William B. Wastila"'
Autor:
William B. Wastila, Paul M. Heerdt, Matthew R. Belmont, Erin Jeannotte, John J. Savarese, Jeff D. McGilvra, Hiroshi Sunaga, Matthew T. Murrell, Farrell E. Cooke
Publikováno v:
Anesthesiology. 129(5)
Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New Background Structure–activity studies were performed to identify a new neuromuscular blocking agent retaining the ultra-short acting characteristics
Autor:
John J. Savarese, Douglas L. Cohn, Vicente Samano, Paul L. Feldman, Michael McNulty, Timothy D. Spitzer, William B. Wastila, Robert A. Mook, Patel Sanjay Shashikant, Eric E. Boros, Mir Hashim, Matthew R. Belmont, Jan-Ake I. Schultz, Philip F. Morgan
Publikováno v:
Anesthesiology. 100:835-845
Background No replacement for succinylcholine is yet available. GW280430A (AV430A) is a representative of a new class of nondepolarizing neuromuscular blocking drugs called asymmetric mixed-onium chlorofumarates. It undergoes rapid degradation in pla
Publikováno v:
Der Anaesthesist. 46:840-849
The benzylisochinoline muscle relaxants have a highly selective affinity to the motor endplate which is associated with an absence of autonomic side effects such as ganglionic and vagus block. The requirement of only low clinical doses also reduces h
Autor:
John J. Savarese, James C. Wisowaty, William B. Wastila, Patel Sanjay Shashikant, R. Brandt Maehr, Mary M. Jackson
Publikováno v:
European Journal of Pharmaceutical Sciences. 5:253-266
The purpose of this work was to identify a new ultra-short-acting neuromuscular blocking agent devoid of the potential to produce cardiovascular effects at ≥ED 9 5 doses. Four new bis -quaternary mivacurium analogues that are acyclic with respect t
Publikováno v:
Current Opinion in Anaesthesiology. 9:S2-S8
Autor:
William B. Wastila, R. Brandt Maehr, Patel Sanjay Shashikant, John J. Savarese, James C. Wisowaty
Publikováno v:
European Journal of Pharmaceutical Sciences. 4:63-71
The purpose of this work was to identify a new ultra-short-acting neuromuscular blocking agent devoid of the potential to produce histamine-like cardiovascular effects at ≥ED 95 doses. Eight new bis -4-benzyltetrahydroisoquinolinium esters, derivat
Autor:
William B. Wastila, John B. Stenlake, Nirmal C. Dhar, John M. Midgley, Luke A. Masterson, R. B. Maehr
Publikováno v:
Journal of Medicinal Chemistry. 39:556-561
Nonsymmetrical bisquaternary mono- and diesters combining the potency-enhancing properties of the (1R)-laudanosinium group with a second unhindered quaternary ammonium moiety have been studied as a means of promoting short action with high-potency ne
Publikováno v:
Anesthesiology Clinics of North America. 11:251-282
SUMMARY Benzylisoquinolinium-based neuromuscular blocking drugs are an established segment of the anesthetic practice pattern. They are nondepolarizing relaxants that do not block the vagus nerve, nor do they cause blockade of sympathetic ganglia. Le
Autor:
J Scharver, J. B. Stenlake, William B. Wastila, CF Henderson, NC Dhar, R. B. Maehr, JM Midgley
Publikováno v:
European Journal of Medicinal Chemistry. 28:415-418
A series of bis-thiazolium diesters has been prepared. All were substantially less potent than atracurium and all showed appreciable vagal blockade at neuromuscular blocking doses. N -Benzyl quaternary substituents shortened the duration of neuromusc